ClinicalTrials.gg
RecruitingNCT07039604Updated Jun 26, 2025

Real-World Study of PADN for the Treatment of PAH

An observational study in Pulmonary Hypertension and Hypertension, Pulmonary Arterial, sponsored by Pulnovo Medical (Wuxi) Co., Ltd.. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-06-26.

Primary conditionPulmonary Arterial HypertensionRegistry: Hypertension, PulmonaryReclassifiedWhy we changed it
Registry
Hypertension, Pulmonary — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Arterial Hypertension
Why
  1. The study's listed conditions name Pulmonary Arterial Hypertension, a narrower term within Hypertension, Pulmonary.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pulnovo Medical (Wuxi) Co., Ltd. · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 76 studies in Pulmonary Arterial Hypertension with a site in China — 19 open to participants now, 24 under way, 3 of them phase 3. Pulmonary Arterial Hypertension · China.

Planned enrollment
13th of 20
200 · median 495
Started
2025
with 2 others
Observational
20 of 76
10 open now
Primary completion
2028-12
later than 17 of 23 live
Registered
72nd of 76
by date

Among the 76 studies in Pulmonary Arterial Hypertension with a site in China, this one is the 13th largest by planned enrollment of the 20 observational ones that give a count, is one of 3 that started in 2025, is one of 20 observational ones, reaches primary completion later than 17 of the 23 other live ones, and was the 72nd registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

19 of the 76 studies in Pulmonary Arterial Hypertension with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Pulmonary Arterial Hypertension with a site in China, or all of them as a file.
02

Study summary

Real-World Study of PADN for the Treatment of PAH

03

Conditions studied

  • Pulmonary Hypertension
  • Hypertension, Pulmonary Arterial

Browse trials for

04

In context

Pulmonary Arterial Hypertension Reclassified

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

This study's planned enrollment of 200 is above the median of 104 across 181 observational studies indexed under Pulmonary Arterial Hypertension.

Browse Pulmonary Arterial Hypertension studies →

Lead sponsor

Pulnovo Medical (Wuxi) Co., Ltd. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients diagnosed with pulmonary arterial hypertension (PAH) who have undergone PADN procedure.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with PAH and received PADN procedure since March 2024.
  2. No to procedure.
  3. Able to provide and authorize use of health/research data.
  4. Compliant with treatment and follow-up requirements.

Exclusion criteria

Exclusion Criteria:

None specified.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Interventions

  • DeviceEnhancor™ Radiofrequency Catheter, Pulnovo Medical (Wuxi) CO., Ltd., Wuxi, Jiangsu, China

    PADN: Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA. The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55 # for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA. For non-atrial fibrillation patients, dual antiplatelet therapy for 1 month after PADN is recommended. Patients with atrial fibrillation should continue new oral anticoagulants and patients who underwent metal valve replacement should continued oral warfarin anticoagulation according to guidelines, which could determined by the physician.

07

What researchers measure

Primary outcomes

  1. Clinical worsening

    Clinical worsening events defined as any of the following during the study period: 1. PAH-related rehospitalization. 2. Addition of PAH-targeted therapies (increased types/dose of PAH-targeted drugs or diuretics). 3. ≥10% or ≥30-meter reduction in 6-Minute Walk Distance (6MWD) from baseline. 4. Atrial septostomy. 5. Need for lung transplantation. 6. Cardiovascular death.

    Time frame: 1 year

Secondary outcomes

  1. WHO Functional Class changes from baseline

    Time frame: 6 months, 1, 2, 3, and 5 years

  2. NT-proBNP/BNP levels from baseline

    Time frame: 6 months, 1, 2, 3, and 5 years

  3. 6MWD changes from baseline

    Time frame: 6 months, 1, 2, 3, and 5 years

  4. Incidence of pulmonary infections

    Time frame: Through study completion, an average of 5 years

  5. All-cause death

    Time frame: Through study completion, an average of 5 years

  6. Echocardiographic changes from baseline

    Right atrial diameter (RAD)

    Time frame: 6 months, 1, 2, 3, and 5 years

  7. Echocardiographic changes from baseline

    Right ventricular end-diastolic diameter (RVDd)

    Time frame: 6 months, 1, 2, 3, and 5 years

  8. Echocardiographic changes from baseline

    Tricuspid annular plane systolic excursion (TAPSE)

    Time frame: 6 months, 1, 2, 3, and 5 years

  9. Echocardiographic changes from baseline

    Left ventricular ejection fraction (LVEF)

    Time frame: 6 months, 1, 2, 3, and 5 years

  10. Echocardiographic changes from baseline

    Left atrial diameter (LAD)

    Time frame: 6 months, 1, 2, 3, and 5 years

  11. Echocardiographic changes from baseline

    Left ventricular end-diastolic diameter (LVDd)

    Time frame: 6 months, 1, 2, 3, and 5 years

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2028, 45 months after the start.

Of 85 observational studies under Pulmonary Arterial Hypertension, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 93. This study's planned 45 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2025
First posted
Jun 26, 2025
StartActual
Mar 19, 2025
Primary completionEst.
Dec 30, 2028
CompletionEst.
Dec 30, 2028
Last update
Jun 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07039604
Lead sponsor
Pulnovo Medical (Wuxi) Co., Ltd.
Responsible party
Sponsor
First posted
Jun 26, 2025
Start date
Mar 19, 2025
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Jun 26, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion